Autopsy report · NCT04952571

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

“Lack of funds”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Beijing Sanbo Brain Hospital

Sponsor type

University, hospital or other

Conditions

Recurrent Glioblastoma

Interventions

Camrelizumab and Bevacizumab

Participants

3

Sites

1

Countries

China

Trials that died the same way

• Metformin in Heart Failure Without Diabetes
  “Lack of funding” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.